Seroconversion of red blood cell antibody screen in ABO-incompatible living donor liver transplantation.
Liver transplantation usually requires blood transfusion and the red blood cell (RBC) antibody screen is essential to prevent a hemolytic reaction. Since the proper ABO-compatible grafts are lacking, ABO-incompatible living donor liver transplantation (ABO-i LDLT) with desensitization is a feasible therapy. Desensitization includes the rituximab and plasmapheresis before the surgery. A 60-year-old female was diagnosed with hepatitis B virus-related hepatocellular carcinoma and planned for ABO-i LDLT. She was positive for RBC antibody screen over 2 years, however, she turned negative for the test after the intravenous rituximab injection and multiple plasmapheresis. The clinicians notified the seroconversion during the induction, so the delay to prepare adequate packed RBC was unavoidable. This case suggests that even when the latest RBC antibody screen is negative after immunosuppression, clinicians should consider the possibility of the prior positive result. Emphasizing those results by the system would be supportive for safer patient management.